{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-22-000038","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.510635+00:00","generated_at":"2026-06-22T23:26:21.451925+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PTC Therapeutics Q3 revenue $217M (+57% YoY); raises DMD full-year guidance; secures $350M Blackstone financing","bullets":["Q3 total revenue $217.1M (+57% YoY); net product revenue $134.2M, royalty and collaboration $82.9M.","DMD franchise net product rev $131.4M (Translarna $76.6M, Emflaza $54.8M); full-year DMD guidance raised to $490-500M.","Strategic financing from Blackstone: initial $350M at close, option for additional $650M low-cost, low-dilution capital.","Net loss improved to $109.3M from $133.6M in Q3 2021; cash $288.4M as of Sep 30, 2022.","Clinical: EMA submission for Translarna standard approval; FDA meeting for Translarna US NDA; Upstaza BLA expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-22-000038","json":"https://secwatch.observer/filing/0001070081-22-000038.json","markdown":"https://secwatch.observer/filing/0001070081-22-000038.md","text":"https://secwatch.observer/filing/0001070081-22-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/0001070081-22-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/tmb-20221027x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:26:21.451925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"120ef8a394f9be1bced021a9aafc1f68c936edd7","claim":"PTC THERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: revenue $217.1 million, net income $(109.3) million. Guidance raised.","evidence_excerpt":"into this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth – - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/0001070081-22-000038-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$217.1 million"},{"label":"Net income","value":"$(109.3) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}